• Open Access

Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease§

Authors

  • Georgia Xiromerisiou MD, PhD,

    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    Search for more papers by this author
  • Henry Houlden PhD, MRCP,

    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    Search for more papers by this author
  • Anna Sailer MD,

    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    Search for more papers by this author
  • Laura Silveira-Moriyama MD, PhD,

    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    Search for more papers by this author
  • John Hardy PhD,

    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    Search for more papers by this author
  • Andrew J. Lees MD, FRCP

    Corresponding author
    1. Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK
    • UCL, IoN, Reta Lila Weston Institute of Neurological Studies, 1 Wakefield Street, London WC1N 1PJ, UK
    Search for more papers by this author

  • Funding agencies: This work was funded by the Reta Lila Weston Trust for Medical Research, and by a Medical Research Council (MRC) returning scientist, by the Wellcome Trust/MRC Parkinson's disease. This work was also supported by the National Institute for Health Research (NIHR)-funded University College London (UCL)/University College London Hospitals (UCLH) Comprehensive Biomedical Research Centre and by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC), whose members are from the UCL Institute of Neurology, the University of Sheffield, and the MRC Protein Phosphorylation Unit at the University of Dundee.

  • Relevant conflicts of interest/financial disclosures: J.H. is on Scientific Advisory Boards for Eisai and Merck Serono. A.L. is on Advisory Boards for Novartis. Teva, Meda, Boehringer Ingelheim, GSK, lpsen, Lundbeck, Allergan. Orion, BIAL, Noscira, and Roche.

  • §

    Full financial disclosures and author roles may be found in the online version of this article.

Analysis of concordancy rates in monozygotic and dizygotic twins with Parkinson's disease (PD) has been an important subject for research into the disorder1 and discordancy between twins has traditionally been interpreted as evidence against a genetic etiology of disease. Discordancy in late-onset diseases such as PD is complicated by the possibility that the disease onset may vary considerably between twins, and cases with up to 20 years of discordance have been reported.2 Leucine-rich repeat-kinase type 2 (LRRK2) mutations are the most common Mendelian cause of PD,3, 4 with the G2109S mutation occurring in 1% to 2% of idiopathic cases in the UK.5 Here we report the identification of a pair of identical twins with this mutation who are discordant by more than 10 years.

The twins, of English descent, are 70+ years old and were self-reported as identical. The proband developed the first symptoms of PD at age 60 years, with unilateral bradykinesia, rigidity, and rest tremor that became bilateral. The initial good response to levodopa therapy was followed in 5 years by development of motor fluctuations with wearing off, on-off effects, and peak dose and diphasic dyskinesias. The family had autosomal dominant inheritance of PD with a parent and 2 second-degree relatives affected by the disorder. On exam, the twin had a normal smell test and no signs of neurodegenerative disorder.

DNA from the proband was sequenced as part of the clinical workup and the heterozygous LRRK2 G2109S mutation was identified. DNA from the twin was sequenced and the mutation was confirmed in the sample. DNA from both twins was run on genomewide arrays (Illumina 660) to confirm that the twins were identical; this also revealed no major chromosomal abnormalities in either twin.

These data show that considerable variance in the penetrance of the mutation can occur even in the context of genetic identity. This suggests that the effects of other genetic loci in modifying the age at onset of disease must be minimal and, therefore, that identifying such loci through linkage or association methods will be extremely challenging because the variability in onset age between LRRK2 mutation carriers6 must be largely nongenetic in etiology. Identifying environmental risk factors for disease is notoriously difficult and there is nothing in the personal or medical histories of these twins that provides obvious clues for the reasons behind the current discordance. Indeed, both twins have had similar life courses. The recent data implicating pathology spread in PD is consistent with the notion that the disease process can start at a single site.7 If this is the case, then a stochastic initiation of disease may underlie the discordance as it may for prion disease.8, 9

Acknowledgements

For reasons of confidentiality minimal clinical details are presented. For further information please contact A.J.L. The funding organizations had no part in the study design or the writing up of this work.

Author Roles: GX carried out the laboratory work, AS helped with the interpretation of the array data, LSM interviewed the proband and reviewed the ethical compliance, HH and JH obtained funds for the work, JH drafted the manuscript which all authors reviewed. AJL identified the patient and initiated the study.

Financial Disclosures: JH is on Scientific Advisory Boards for Eisai and Merck Serono. AL is on Advisory Boards for Novartis. Teva, Meda, Boehringer Ingelheim, GSK, lpsen, Lundbeck, Allergan. Orion, BIAL, Noscira and Roche. None of the other authors have consultancy or advisory roles.

Note Added in Proof

Author Roles: GX carried out the laboratory work, AS helped with the interpretation of the array data, LSM interviewed the proband and reviewed the ethical compliance, HH and JH obtained funds for the work, JH drafted the manuscript which all authors reviewed. AJL identified the patient and initiated the study.

Financial Disclosures: JH is on Scientific Advisory Boards for Eisai and Merck Serono. AL is on Advisory Boards for Novartis. Teva, Meda, Boehringer Ingelheim, GSK, lpsen, Lundbeck, Allergan. Orion, BIAL, Noscira and Roche. None of the other authors have consultancy or advisory roles.

Georgia Xiromerisiou MD, PhD*, Henry Houlden PhD, MRCP*, Anna Sailer MD*, Laura Silveira-Moriyama MD, PhD*, John Hardy PhD*, Andrew J. Lees MD, FRCP*, * Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, University College London (UCL) Institute of Neurology, Queen Square, London, UK.

Ancillary